<SEC-DOCUMENT>0001213900-25-126654-index.html : 20251230
<SEC-HEADER>0001213900-25-126654.hdr.sgml : 20251230
<ACCEPTANCE-DATETIME>20251230163001
ACCESSION NUMBER:		0001213900-25-126654
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20251230
FILED AS OF DATE:		20251230
DATE AS OF CHANGE:		20251230

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anbio Biotechnology
		CENTRAL INDEX KEY:			0001982708
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42526
		FILM NUMBER:		251614654

	BUSINESS ADDRESS:	
		STREET 1:		FRIEDRICH-EBERT-ANLAGE 49
		CITY:			FRANKFURT AM MAIN
		STATE:			2M
		ZIP:			60308
		BUSINESS PHONE:		4916096247281

	MAIL ADDRESS:	
		STREET 1:		FRIEDRICH-EBERT-ANLAGE 49
		CITY:			FRANKFURT AM MAIN
		STATE:			2M
		ZIP:			60308
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0271224-6k_anbio.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
Document 1 - file: ea0271224-6k_anbio.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea027122401ex99-1_anbio.htm
<DESCRIPTION>PRESS RELEASE - ANBIO BIOTECHNOLOGY ANNOUNCED UNAUDITED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025
<TEXT>
Document 2 - file: ea027122401ex99-1_anbio.htm

</DOCUMENT>
</SEC-DOCUMENT>